Mantle cell lymphoma (MCL) is an aggressive, difficult to treat subtype of lymphoma, resulting in relapses and poor outcomes. Novel agents such as Bruton tyrosine kinase (BTK) inhibitors have been studied in the treatment of relapsed/refractory (R/R) MCL. BTK inhibitor ibrutinib, in particular, has demonstrated improvement in survival outcomes of R/R MCL. Despite these advancements, many cases of MCL, including the more aggressive blastoid and pleomorphic variants, will undergo disease progression leading to poor survival outcomes. Blastoid variant MCL is associated with an increased risk of central nervous system (CNS) involvement, causing high mortality rates. In this case report, we discuss a patient with a diagnosis of blastoid MCL with CNS relapse who achieved a complete response (CR) after receiving standard rituximab plus ifosfamide-carboplatin-etoposide (R-ICE) salvage chemotherapy with the addition of ibrutinib. The patient subsequently underwent autologous stem cell transplantation (autoSCT) and maintained CR with ibrutinib maintenance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106524 | PMC |
| http://dx.doi.org/10.1155/2022/1930546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
Br J Haematol
December 2024
Hematology, School of Medicine, Università degli Studi di Milano, Milan, Italy.
Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral blood monitored in 61 of them. Clinical outcomes and toxicities are consistent with previous real-world evidence studies.
View Article and Find Full Text PDFA rapid progression from classical mantle cell lymphoma to a blastoid variant.
Leuk Res Rep
November 2024
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie biologique, Pierre-Bénite, France.
This case report presents an 82-year-old male initially diagnosed with classical mantle cell lymphoma (MCL) that progressed to the aggressive blastoid variant. The patient was initially treated with oral chemotherapy (PEP-C), followed by ibrutinib, but experienced disease progression with central nervous system (CNS) involvement and blastoid morphology. Despite subsequent intensive treatment, including high-dose cytarabine (Cytarabine), rituximab, and intrathecal methotrexate (Methotrexate), the patient's disease continued to advance, resulting in death.
View Article and Find Full Text PDFUpfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies.
Cancer Med
October 2024
Department of Medicine, Division of Hematology Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
Article Synopsis
- Blastoid variant-mantle cell lymphoma (BV-MCL) is a serious condition with no standard treatment, prompting a study of 17 patients at a medical institution from 2009 to 2023.
- The study found that the overall response to initial treatment was 66.7%, but the overall survival rate after two years was only 62.5%, influenced by factors like type of therapy and genetic variations.
- New BTK inhibitor therapies show promise for improving outcomes in these high-risk patients, especially for those without TP53 mutations.
[Update on treatment strategies for mantle cell lymphoma].
Rinsho Ketsueki
October 2024
Department of Hematology, National Cancer Center Hospital.
Mantle cell lymphoma (MCL) is a type of lymphoid malignancy that is rare in Japan. MCL is refractory to conventional chemotherapy and has dismal outcomes. Nonetheless, the prognosis of MCL has gradually improved with the advent of autologous stem cell transplantation and BTK inhibitors.
View Article and Find Full Text PDFAtypical Plasma Cell Leukemia Mistaken for Acute Leukemia: A Case Report.
Medicina (Kaunas)
August 2024
Department of Pathology, Faculty of Medicine, University of Rijeka, Clinical Hospital Center Rijeka, 51000 Rijeka, Croatia.
The patient we present here had many clinical, morphological, and laboratory findings characteristic of acute leukemia. During the course of the disease, the diagnosis changed from acute leukemia to chronic small B-cell lymphoproliferative disease, a blastoid variant of mantle cell lymphoma, and finally to atypical plasma cell leukemia. Atypical plasma cell leukemia is a rare condition with aggressive biological behavior.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!